Multivalent protein and screening method
By developing multivalent protein scaffolds, the problems of high production cost and high risk of immune response of existing protein therapeutics have been solved, and efficient and low-cost screening and design of protein therapeutics have been achieved.
CN120659804APending Publication Date: 2025-09-16VALINK THERAPEUTICS LTD
8 Cites 0 Cited by
Patent Information
- Application Number
- CN202380081869.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-16
- Filing Date
- 2023-09-28
- Publication Date
- 2025-09-16
AI Technical Summary
Technical Problem
Existing protein therapeutics have high production costs, complex production processes and low efficiency, while antibody therapeutics diffuse slowly in the body and have a high risk of immune response, making them difficult to use widely.
Method used
Develop multivalent protein scaffolds, including oligomeric cores of multiple subunit monomers and orthogonal binding sites, prepared through genetic engineering or chemical coupling methods to achieve efficient binding and screening of peptide targets.
Benefits of technology
It enables the rapid, scalable, and adaptable identification and design of protein therapeutics, reducing production costs, improving treatment efficiency, and reducing the risk of immune response.
✦ Generated by Eureka AI based on patent content.
Abstract
The present application provides multivalent protein scaffolds useful as therapeutic agents and useful for identifying novel therapeutic compounds. The invention also relates to multi-domain polypeptide constructs having a plurality of binding domains and a domain. The invention also provides a method for identifying a new candidate therapeutic agent by using the multivalent protein scaffold provided by the invention and the identified new therapeutic agent.
Need to check novelty before this filing date? Find Prior Art